The p53/p21Cip1/Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression

Pigment Cell and Melanoma Research

Volumn 24, Issue 1, 2011, Pages 219-232

  Fenouille, Nina ^a,b   Robert, Guillaume ^a,b   Tichet, Mélanie ^a,b   Puissant, Alexandre ^b,c   Dufies, Maeva ^a,b   Rocchi, Stéphane ^a,b,d   Ortonne, Jean Paul ^a,d   Deckert, Marcel ^b,c,d   Ballotti, Robert ^a,b,d   Tartare Deckert, Sophie ^a,b,d  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Cell cycle; Cell migration; Melanoma; P53; SPARC

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; OSTEONECTIN; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; MELANOMA CELL; MITOSIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BIOLOGICAL MODEL; CANCER INVASION; CELL CYCLE G2 PHASE; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITOSIS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; OSTEONECTIN; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651454767     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00790.x     Document Type: Article

References (56)

1. Abbas, T., and Dutta, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400-414.
2. Albino, A.P., Vidal, M.J., McNutt, N.S., Shea, C.R., Prieto, V.G., Nanus, D.M., Palmer, J.M., and Hayward, N.K. (1994). Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4, 35-45.
3. Alexaki, V.I., Javelaud, D., and Mauviel, A. (2008). JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 21, 429-438.
4. Alonso, S.R., Tracey, L., Ortiz, P. et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67, 3450-3460.
5. Alvarez, M.J., Prada, F., Salvatierra, E., Bravo, A.I., Lutzky, V.P., Carbone, C., Pitossi, F.J., Chuluyan, H.E., and Podhajcer, O.L. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res. 65, 5123-5132.
6. Bailet, O., Fenouille, N., Abbe, P. et al. (2009). Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res. 69, 2748-2756.
7. Baus, F., Gire, V., Fisher, D., Piette, J., and Dulic, V. (2003). Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J. 22, 3992-4002.
8. Besson, A., Dowdy, S.F., and Roberts, J.M. (2008). CDK inhibitors: cell cycle regulators and beyond. Dev. Cell. 14, 159-169.
9. Bhoopathi, P., Chetty, C., Gujrati, M., Dinh, D.H., Rao, J.S., and Lakka, S. (2010). Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ. 17, 1529-1539.
10. Bornstein, P., and Sage, E.H. (2002). Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14, 608-616.
11. Bradshaw, A.D., and Sage, E.H. (2001). SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107, 1049-1054.
12. Brekken, R.A., and Sage, E.H. (2001). SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19, 816-827.
13. Brekken, R.A., Puolakkainen, P., Graves, D.C., Workman, G., Lubkin, S.R., and Sage, E.H. (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest. 111, 487-495.
14. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501.
15. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L., and Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769.
16. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
17. Chlenski, A., Liu, S., Crawford, S.E. et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 62, 7357-7363.
18. Clark, C.J., and Sage, E.H. (2008). A prototypic matricellular protein in the tumor microenvironment - where there's SPARC, there's fire. J. Cell. Biochem. 104, 721-732.
19. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
20. Elledge, S.J. (1996). Cell cycle checkpoints: preventing an identity crisis. Science 274, 1664-1672.
21. Flatt, P.M., Tang, L.J., Scatena, C.D., Szak, S.T., and Pietenpol, J.A. (2000). p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 20, 4210-4223.
22. Ford, R., Wang, G., Jannati, P., Adler, D., Racanelli, P., Higgins, P.J., and Staiano-Coico, L. (1993). Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp. Cell Res. 206, 261-275.
23. Gaggioli, C., Deckert, M., Robert, G., Abbe, P., Batoz, M., Ehrengruber, M.U., Ortonne, J.P., Ballotti, R., and Tartare-Deckert, S. (2005). HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene 24, 1423-1433.
24. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
25. Haass, N.K., Smalley, K.S., Li, L., and Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 18, 150-159.
26. Horie, K., Tsuchihara, M., and Nakatsura, T. (2010). Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci. 101, 913-919.
27. Infante, J.R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A.P., Riall, T.A., Yeo, C., Iacobuzio-Donahue, C., and Goggins, M. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 25, 319-325.
28. Koukourakis, M.I., Giatromanolaki, A., Brekken, R.A., Sivridis, E., Gatter, K.C., Harris, A.L., and Sage, E.H. (2003). Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 63, 5376-5380.
29. Lakin, N.D., and Jackson, S.P. (1999). Regulation of p53 in response to DNA damage. Oncogene 18, 7644-7655.
30. Ledda, M.F., Adris, S., Bravo, A.I., Kairiyama, C., Bover, L., Chernajovsky, Y., Mordoh, J., and Podhajcer, O.L. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3, 171-176.
31. Liu, M., Casimiro, M.C., Wang, C. et al. (2009). p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc. Natl Acad. Sci. U S A 106, 19035-19039.
32. Massi, D., Franchi, A., Borgognoni, L., Reali, U.M., and Santucci, M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol. 30, 339-344.
33. Miller, A.J., and Mihm Jr, M.C. (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
34. O'Connor, P.M., Jackman, J., Bae, I. et al. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300.
35. Podhajcer, O.L., Benedetti, L.G., Girotti, M.R., Prada, F., Salvatierra, E., and Llera, A.S. (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 27, 691-705.
36. Prada, F., Benedetti, L.G., Bravo, A.I., Alvarez, M.J., Carbone, C., and Podhajcer, O.L. (2007). SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J. Invest. Dermatol. 127, 2618-2628.
37. Puolakkainen, P.A., Brekken, R.A., Muneer, S., and Sage, E.H. (2004). Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2, 215-224.
38. Riley, T., Sontag, E., Chen, P., and Levine, A. (2008). Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412.
39. Robert, G., Gaggioli, C., Bailet, O. et al. (2006). SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 66, 7516-7523.
40. Said, N., Socha, M.J., Olearczyk, J.J., Elmarakby, A.A., Imig, J.D., and Motamed, K. (2007). Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res. 5, 1015-1030.
41. Said, N., Frierson Jr, H.F., Chernauskas, D., Conaway, M., Motamed, K., and Theodorescu, D. (2009). The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 28, 3487-3498.
42. Sangaletti, S., and Colombo, M.P. (2008). Matricellular proteins at the crossroad of inflammation and cancer. Cancer Lett. 267, 245-253.
43. Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M.R., and Colombo, M.P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J. Exp. Med. 198, 1475-1485.
44. Sangaletti, S., Di Carlo, E., Gariboldi, S., Miotti, S., Cappetti, B., Parenza, M., Rumio, C., Brekken, R.A., Chiodoni, C., and Colombo, M.P. (2008). Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res. 68, 9050-9059.
45. Shi, Q., Bao, S., Maxwell, J.A., Reese, E.D., Friedman, H.S., Bigner, D.D., Wang, X.F., and Rich, J.N. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J. Biol. Chem. 279, 52200-52209.
46. Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D.D., Hjelmeland, A.B., and Rich, J.N. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26, 4084-4094.
47. Smit, D.J., Gardiner, B.B., and Sturm, R.A. (2007). Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int. J. Cancer 121, 2653-2660.
48. Smits, V.A., Klompmaker, R., Vallenius, T., Rijksen, G., Makela, T.P., and Medema, R.H. (2000). p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J. Biol. Chem. 275, 30638-30643.
49. Sturm, R.A., Satyamoorthy, K., Meier, F., Gardiner, B.B., Smit, D.J., Vaidya, B., and Herlyn, M. (2002). Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res. 62, 226-232.
50. Tang, M.J., and Tai, I.T. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem. 282, 34457-34467.
51. Taylor, W.R., and Stark, G.R. (2001). Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815.
52. Taylor, W.R., Schonthal, A.H., Galante, J., and Stark, G.R. (2001). p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J. Biol. Chem. 276, 1998-2006.
53. Weiss, J., Schwechheimer, K., Cavenee, W.K., Herlyn, M., and Arden, K.C. (1993). Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54, 693-699.
54. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
55. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
56. Yiu, G.K., Chan, W.Y., Ng, S.W., Chan, P.S., Cheung, K.K., Berkowitz, R.S., and Mok, S.C. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159, 609-622.